Johnson & Johnson to acquire Abiomed

Johnson & Johnson on Tuesday announced its plans to acquire Abiomed, which develops technologies for heart, lung and kidney support, in a deal worth more than $16 billion. 

WHY IT MATTERS

The purchase will help to advance the standard of care in heart failure and recovery worldwide, according to Johnson & Johnson. 

Abiomed will operate as a standalone business within Johnson & Johnson MedTech, becoming one of the company’s dozen “priority…